Name
AVEO Oncology, an LG Chem company
Company Description
AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 19, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com.
Website
Featured Exhibitor
Yes
Product Categories (7)
Genitourinary Cancer, Head and Neck Cancer, Biotechnology, Clinical Trials, Drug Development, Pharmaceutical
Phone (If provided, phone will display online and in-print)
857-400-0101
Address
Boston, MA
United States
United States
Recognition
